Cybin Corp. Announces Reverse Take-Over Transaction and the Engagement of Stifel GMP and Eight Capital to Co-Lead ConcurHAVN Life Sciences Continues To Execute On Growth Initiatives Ahead Of Its Upcoming Public ListingMindMed Developing IP For Personalized Psychedelic Assisted TherapiesNuminus announces Clinical Advisory Council to advance integrated wellness modelRritual Announces Dr. Mike Hart as PresidentThe Multi-Billion Dollar Functional Mushroom Market Is Up For GrabsMydecine Innovations Group Bolsters Scientific Advisory Board Adding a Leading Neuroscientist and a Psychopharmacology SField Trip Is Shifting Gears To Expedite IPO ProcessMydecine Innovations Group Signs Definitive Agreement to Acquire Mindleap Health’s Advanced Digital Telehealth PlatforNew Wave Holdings Corp Appoints Dr. Carolyn Myers As VP Of Commerical DevelopmentNew Wave Holdings Corp Appoints Dr. Dennis McKenna to Psychedelic Research Advisory BoardChampignon Provides Corporate Update; Announces Name Change, Rebranding and Planned Spin OutRed Light Holland Announces Closing of Second Tranche of Private PlacementNuminus Wellness Has Big Plans To Scale Operations In The Back Half of 2020 Following A Major License Amendment By HealtMydecine Innovations Group Inc. Signs Partnership Agreement With Applied Pharmaceutical InnovationCybin Corp: A Mushroom Life Sciences Leader In The MakingChampignon Announces Closing of $15 Million Bought Deal Private PlacementNuminus receives Health Canada licence amendment to produce and extract psilocybin from mushroomsPharmaDrug Receives Conditional Approval for Grant of OptionsWake Network Is Creating A Multi-Faceted Platform To Bring Psychedelic Therapies To Market
Back

Wake Network Is Creating A Multi-Faceted Platform To Bring Psychedelic Therapies To Market

Jun 9, 2020 • 5:05 PM EDT
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

During the last month, we have seen a substantial increase in the amount of interest in the psychedelic market and this is an opportunity that we are closely following. We have been focused on identifying potential leaders in the psychedelic market and want to highlight a business that caught our attention.

WAKE Network is an emerging opportunity that is focused on advancing fungi and plant-based medicine by leveraging clinical research, wellness professionals, and technology. The company has developed a regenerative feedback loop that allows it to research, monitor and incorporate results from clinical studies to personalize medicine to reduce the level of ambiguous results from traditional medicine.

One of the reasons we are excited about WAKE is related to the structure of the business. The company operates an integrated business model that provides it with multiple revenue streams and we are bullish on the amount of synergies that can found between the following divisions:

  1. Clinics: Has a clinical immersion platforms in Jamaica, the Netherlands, California, the British Virgin Islands, and Brazil.
  2. Research: Formed strategic partnerships that are focused on R&D and technology
  3. Products: Develops and sells functional mushroom supplements through a direct-to-consumer model. The company plans to expand to plant medicine and psilocybin derived treatments
  4. Intellectual Property (IP): The company is working on being granted patents for proprietary formulations, strains, dosing, therapy protocols, and delivery methods

Earlier this year, Wake Clinics opened a 3,000-acre mountain retreat, private beach and pavilion in Jamaica. The facility offers psilocybin-based therapy where licensed professionals assess patients and track biofeedback. Therapists who work at the clinic provide ongoing monitoring to ensure the full integration of the healing process.

One of the ways WAKE Network has been able to differentiate itself is through the work it has accomplished in Jamaica. Wake Jamaica is a separate division of the business and is a cultivation-focused joint venture subsidiary that is managed by Pauline Smith and her group of mycologists and farmers. We are bullish on the growth prospects that are associated with the division and will monitor how this aspect of the story advances from here.

The other division of WAKE is focused on the development of a line of premium functional mushroom products. During the last decade, we have seen a substantial increase in the level of demand for functional mushrooms and are bullish on the trend. All of the functional mushrooms that produced by WAKE are organic and we are favorable on this aspect of the story.

From a management team standpoint, WAKE Network is led by a team that has diverse expertise in a variety of industries and we find this to be significant. Dr. Olga Chernoloz is one of the most important members of the team and is the director of the psychedelic research at Wake Network.

We are favorable on the experience that Dr. Chernoloz brings to the business. Dr Chernoloz serves as a scientific advisor to The Toronto Centre for Psychedelic Science and has extensive experience providing scientific advisory services to cannabis and psychedelic companies. Dr Chernoz will play a key role in the success of the business.

WAKE Network represents a differentiated opportunity with significant potential catalysts. Over the next year, we expect the company to record notable advancements related to the assets in Jamaica and with its clinics. This is an opportunity that we will be putting on our radar and will provide updates as needed.

If you are interested in learning WAKE Network, please send an email to support@technical420.com to be added to our distribution list.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link